CN101310758A - Anti-anxiety compound traditional Chinese medicine and preparation method thereof - Google Patents
Anti-anxiety compound traditional Chinese medicine and preparation method thereof Download PDFInfo
- Publication number
- CN101310758A CN101310758A CNA200710041130XA CN200710041130A CN101310758A CN 101310758 A CN101310758 A CN 101310758A CN A200710041130X A CNA200710041130X A CN A200710041130XA CN 200710041130 A CN200710041130 A CN 200710041130A CN 101310758 A CN101310758 A CN 101310758A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- chinese medicine
- radix
- pharmaceutical composition
- volatile oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition, which comprises the following necessary components: (a) 30 to 200 parts by weight of traditional Chinese medicine containing volatile oil, and the traditional Chinese medicine containing the volatile oil comprises nutgrass galingale rhizome, grassleaf sweelflag rhizome, turmeric root-tuber and villous amomum fruit; (b) 100 to 400 parts by weight of the traditional Chinese medicine containing water-soluble ingredients, and the traditional Chinese medicine containing the water-soluble ingredients comprises Chinese thorowax root, green tangerine peel, silktree albizzia bark, Indian buead, membranous milkvetch root, spina date seed and white paeony root. The pharmaceutical composition has the effects of relaxing liver, strengthening spleen, resolving stagnation for tranquilization and effectiveness of anti-depression; furthermore, the price is cheap and the pharmaceutical composition can be used within a larger range.
Description
Technical field
The present invention relates to Chinese medicine composition, more specifically, relate to the Chinese medicine composition for the treatment of depression or dietary supplement and preparation method thereof.
Background technology
Depression or depressive disorder are global main Mental health problems, its cause of disease is very complicated, so far do not illustrate fully as yet, along with modern society strives aggravation day by day unexpectedly, people's mental pressure constantly increases, feelings will disease becomes the principal disease in the present age, and World Health Organization (WHO) points out that the maximum disease that the 21st century people face is a mental sickness.WHO estimates that the depressive illness person is suffered from the whole world 1.2 hundred million to 200,000,000 people.1996, the investigation about " disease burden " that WHO announces showed: due to illness to cause permanent disability (functional impairment) statistics, depression accounts for second, accounts for 6.2% of the total burden of whole diseases.This class patient is depressed, association slowly, the speech action reduces, inner experience is very painful, and thoughts of suicide and suicide are often arranged, according to reports abroad only depression committed suicide rate just up to 15%.The depression lifetime prevalence is 6.1-9.5%, and the people of about 13-20% once had once or once above depressed experience all one's life.Along with development, the rhythm of life of society are accelerated, depression is growth year by year, estimates after 25 years, will account for the total burden about 10% of disease.
At present, the chemicals for the treatment of depression in the world mainly contains, and three ring antidepressants (TCAS) are as nortriptyline and desmethylimipramine etc., oxidase inhibitor (MAOLS), as phenelzine, tranylcypromine and isocarbossazide etc., selectivity 5-HT reuptake inhibitor (SSRLS), as fluoxetine, Clovoxamine, Sertraline etc., another kind is the lithium preparation, and lithium is used for treating manic depression, and some major depression that often recurs.These chemicalses often cause many untoward reaction, as calmness, insomnia, postural hypotension, urine retention, feel sick, vomiting and interact with food.
Modern medicine is still indeterminate to the depression pathogenesis.New antidepressant drug also emerges in an endless stream, but because narrow its adverse side effect of antidepressant spectrum is many, addiction is big and contraindication is many, has seriously restricted clinical use.The antidepressants that China's existing market is sold mainly are Western medicine, cost an arm and a leg, and are not suitable for China's actual conditions.
Therefore, this area presses for provides a kind of good effect, little, the moderate antidepressant drug of side effect.
Summary of the invention
The present invention aims to provide a kind of pharmaceutical composition and preparation method thereof.
Another object of the present invention is a kind of dietary supplement.
A further object of the present invention provides the purposes of aforementioned pharmaceutical compositions.
In a first aspect of the present invention, a kind of pharmaceutical composition is provided, it contains necessary component or its extract that is selected from down group:
(a) the 30-200 weight portion contains the Chinese medicine of volatile oil, and the described Chinese medicine that contains volatile oil comprises Rhizoma Cyperi, Rhizoma Acori Graminei, Radix Curcumae and Fructus Amomi;
(b) the 100-400 weight portion contains the Chinese medicine of water-soluble components, and the described Chinese medicine that contains water-soluble components comprises Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Cortex Albiziae, Poria, the Radix Astragali, Semen Ziziphi Spinosae and the Radix Paeoniae Alba;
And weight (a)+(b) accounts for the 30-99.9% of composition total weight, and the pharmaceutically acceptable carrier of surplus.
In another preference, the described Chinese medicine that contains water-soluble components also comprises Fructus Aurantii.
In another preference, it contains necessary component or its extract that is selected from down group:
10-40 weight portion Radix Bupleuri;
10-40 weight portion Rhizoma Cyperi;
10-40 weight portion Fructus Aurantii;
10-40 weight portion Pericarpium Citri Reticulatae Viride;
10-50 weight portion Cortex Albiziae;
10-40 weight portion Rhizoma Acori Graminei;
10-40 weight portion Radix Curcumae;
20-60 weight portion Poria;
The 20-60 weight portion Radix Astragali;
5-30 weight portion Fructus Amomi;
30-100 weight portion Semen Ziziphi Spinosae;
The 10-40 weight portion Radix Paeoniae Alba.
In another preference, described compositions contains necessary component or its extract that is selected from down group:
15-35 weight portion Radix Bupleuri;
15-35 weight portion Rhizoma Cyperi;
15-35 weight portion Fructus Aurantii;
15-35 weight portion Pericarpium Citri Reticulatae Viride;
20-45 weight portion Cortex Albiziae;
15-35 weight portion Rhizoma Acori Graminei;
15-35 weight portion Radix Curcumae;
30-55 weight portion Poria;
The 30-55 weight portion Radix Astragali;
10-25 weight portion Fructus Amomi;
50-90 weight portion Semen Ziziphi Spinosae;
The 15-35 weight portion Radix Paeoniae Alba.
In another preference, described compositions contains necessary component or its extract that is selected from down group:
20-30 weight portion Radix Bupleuri;
20-30 weight portion Rhizoma Cyperi;
20-30 weight portion Fructus Aurantii;
20-30 weight portion Pericarpium Citri Reticulatae Viride;
30-40 weight portion Cortex Albiziae;
20-30 weight portion Rhizoma Acori Graminei;
20-30 weight portion Radix Curcumae;
35-50 weight portion Poria;
The 35-50 weight portion Radix Astragali;
12-20 weight portion Fructus Amomi;
60-80 weight portion Semen Ziziphi Spinosae;
The 20-30 weight portion Radix Paeoniae Alba.
In another preference, following medicinal substances extract is an aqueous extract: Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Fructus Aurantii, Cortex Albiziae, Poria, the Radix Astragali, Semen Ziziphi Spinosae or the Radix Paeoniae Alba;
Following medicinal substances extract is volatile oil and water extract: Rhizoma Cyperi, Rhizoma Acori Graminei, Radix Curcumae or Fructus Amomi.
In another preference, described aqueous extract is that ethanol content is the aqueous solution of 40-95% (v/v).
In another preference, in described compositions, content of paeoniflorin is 0.1-1.0wt%.0.2-0.6wt% preferably.
In another preference, the dosage form of described compositions is tablet, decoction, granule, capsule preparations, oral liquid.
In another preference, described dosage form is tablet or capsule.More preferably, the specification of described capsule or tablet is 0.3-0.6 or 0.3-0.6mg/ agent.
In another preference, Determination of Hesperidin Content 0.1-1.0wt%, 0.2-0.5wt% preferably, the content 0.01-1wt% of astragaloside, the content 0.01-2wt% of α-cyperone.
In a second aspect of the present invention, a kind of dietary supplement is provided, it contains necessary component or its extract that is selected from down group:
(a) the 30-200 weight portion contains the Chinese medicine of volatile oil, and the described Chinese medicine that contains volatile oil comprises Rhizoma Cyperi, Rhizoma Acori Graminei, Radix Curcumae and Fructus Amomi;
(b) the 100-400 weight portion contains the Chinese medicine of water-soluble components, and the described Chinese medicine that contains water-soluble components comprises Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Cortex Albiziae, Poria, the Radix Astragali, Semen Ziziphi Spinosae and the Radix Paeoniae Alba;
And weight (a)+(b) accounts for the 30-99.9% of composition total weight, and the pharmaceutically acceptable carrier of surplus.
In a third aspect of the present invention, a kind of above-mentioned preparation of drug combination method is provided, it comprises step:
(1) necessary component or its extract are mixed, obtain mixture, described necessary component is the Chinese medicine that (a) 30-200 weight portion contains volatile oil, and the described Chinese medicine that contains volatile oil comprises Rhizoma Cyperi, Rhizoma Acori Graminei, Radix Curcumae and Fructus Amomi; (b) the 100-400 weight portion contains the Chinese medicine of water-soluble components, and the described Chinese medicine that contains water-soluble components comprises Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Cortex Albiziae, Poria, the Radix Astragali, Semen Ziziphi Spinosae and the Radix Paeoniae Alba;
(2) the pharmaceutically acceptable carrier of adding surplus in the mixture of step (1) gained makes pharmaceutical composition provided by the invention;
And weight (a)+(b) accounts for the 30-99.9% of composition total weight.
In another preference, it comprises step:
(1) necessary component or its extract are mixed, obtain mixture, described necessary component comprises 10-40 weight portion Radix Bupleuri, 10-40 weight portion Rhizoma Cyperi, 10-40 weight portion Fructus Aurantii, 10-40 weight portion Pericarpium Citri Reticulatae Viride, 10-50 weight portion Cortex Albiziae, 10-40 weight portion Rhizoma Acori Graminei, 10-40 weight portion Radix Curcumae, 20-60 weight portion Poria, the 20-60 weight portion Radix Astragali, 5-30 weight portion Fructus Amomi, 30-100 weight portion Semen Ziziphi Spinosae, the 10-40 weight portion Radix Paeoniae Alba;
(2) the pharmaceutically acceptable carrier of adding surplus in the mixture of step (1) gained makes pharmaceutical composition provided by the invention.
In another preference, in step (1), following medical material adds with the aqueous extract form: Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Fructus Aurantii, Cortex Albiziae, Poria, the Radix Astragali, Semen Ziziphi Spinosae or the Radix Paeoniae Alba;
Following medical material adds with volatile oil and water extract form: Rhizoma Cyperi, Rhizoma Acori Graminei, Radix Curcumae or Fructus Amomi;
Described aqueous extract is that ethanol content is the aqueous solution of 40-95% (v/v).
In a fourth aspect of the present invention, the purposes of the extract of a kind of mixture or described mixture is provided, described mixture contains the Chinese medicine that (a) 30-200 weight portion contains volatile oil, and the described Chinese medicine that contains volatile oil comprises Rhizoma Cyperi, Rhizoma Acori Graminei, Radix Curcumae and Fructus Amomi; (b) the 100-400 weight portion contains the Chinese medicine of water-soluble components, the described Chinese medicine that contains water-soluble components comprises Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Cortex Albiziae, Poria, the Radix Astragali, Semen Ziziphi Spinosae and the Radix Paeoniae Alba, and the extract of described mixture or described mixture can be used for preparing the medicine for the treatment of depression.
In view of the above, the invention provides a kind of good effect, side effect is little, moderate antidepressant drug.
The specific embodiment
The inventor according to the theory of the relevant melancholia of the traditional Chinese medical science, has been surprised to find that the Chinese medicine composition of a kind of energy dispersing the stagnated live-QI to relieve the stagnation of QI, spleen-benefiting mind-tranquilizing through extensive and deep research.Specifically, Radix Bupleuri dispersing the stagnated live-QI to relieve the stagnation of QI in the compositions is monarch drug; Rhizoma Cyperi, Pericarpium Citri Reticulatae Viride, Cortex Albiziae, Radix Curcumae, Rhizoma Acori Graminei, Poria, Fructus Amomi, the Radix Astragali are ministerial drug altogether, wherein Rhizoma Cyperi, Pericarpium Citri Reticulatae Viride, Cortex Albiziae are regulated the flow of vital energy and middle relieving distension, the pain relieving of Radix Curcumae resolving depression promoting flow of QI and blood, Rhizoma Acori Graminei have one's ideas straightened out eliminating phlegm removing dampness appetizing, refreshment Fructus Alpiniae Oxyphyllae, Poria, Fructus Amomi invigorating the spleen for eliminating dampness, regulating qi-flowing for harmonizing stomach, Radix Astragali invigorating the spleen and benefiting QI yang invigorating; The Radix Paeoniae Alba, Semen Ziziphi Spinosae are using corrigent, change cloudy, nourishing the liver blood and tranquilizing mind.Clinical research shows that this is a scientific and effective prescription.
Depressive state is common in depression (unipolar depression), depressive neurosis, anxiety neurosis and the reactive depression etc. of affective disorders.The melancholia that the traditional Chinese medical science is alleged, be equivalent to the depressive states that disease occurred such as the depressive state of depressive neurosis, anxiety neurosis, affective psychosis of modern medicine indication and masked depression, menopausal depression, neurosis, mostly being psychogenic disorder, is the pathological changes that brain ergasia obstacle is caused.
Melancholia is because feelings will is not relaxed the caused class disease of depression and stagnation of QI.Mainly show as and feel depressed, irritable emotion, distending pain over the hypochondrium, or irritability is kind cries, and block various complicated symptoms such as insomnia if any foreign body in the pharynx.Its normal manner is lost in feelings will fluctuation, depression and stagnation of QI then, and with the passing of time the stagnation of QI does not heal, and by gas and blood, becomes and gives birth to multiterminal, can cause multiple symptom, so saying of " six kinds of stagnation-syndromes " arranged.Being six kinds of the stagnation of QI, blood stagnation, phlegm stagnancy, damp-stagnancy, heat stagnation, food stagnancy etc., wherein is earlier with the stagnation of QI, all strongly fragrant could formation such as then wet, expectorant, heat, blood, food.
The generation of melancholia is because feelings will is hindered, and depression of liver-QI causes due to the five internal organs mechanism of qi discord gradually.But mainly being that liver, spleen, the heart three are dirty gets involved and disorder of QI and blood forms:
(1) disgruntled not smooth, make liver lose bar and reach, gas loses catharsis, and causes depression of liver-QI.The stagnation of QI with the passing of time can fire-transformation, and the stagnation of QI can cause blood stasis not all right again.If stagnation of liver-QI and spleen, or ponder over puzzledly, overstrain impairing the spleen all can make dysfunction of the spleen in transportation, accumulates humidogene expectorant, causes stagnation of QI phlegm stagnancy.If turbid damp stops, or dyspepsia do not disappear, or the phlegm-damp heat-transformation, then can develop into cards such as damp-stagnancy, food stagnancy, heat stagnation.
(2) feelings will is unsuccessful, and stagnation of liver-QI presses down spleen, consumes sad gas, and nutrient blood gradually consumes, and the heart is become homeless foster, the god Tibetan of becoming homeless, and promptly so-called melancholy is overtaxed one's nerves, and can cause irritability.If chronic depression impairing the spleen, diet reduces, biochemical weary source, and insufficiency of vital energy and blood then, deficiency of both the heart and spleen, the easy impairment of YIN blood of strongly fragrant fire-transformation of a specified duration involves in kidney, hyperactivity of fire caused by deficiency of YIN, development can become all deficient times thus.
Melancholia because of disgruntled, ponder over, institute grieved, worried seven emotions hinders, and causes the liver failing to maintain the normal flow of QI, spleen mistake fortuneization, the mind is not normal, the internal organs yin and yang qi and blood disorder forms.The first cause of disease stagnation of QI and hold damp-phlegm, food stagnation, heat stagnation person under the arm, then how true card; Prolonged illness is by gas and blood, and Sthenia is transforming into asthenia, overtaxes one's nerves as for a long time strongly fragrant, and heart spleen all loses, and hyperactivity of fire caused by deficiency of YIN etc. all belong to deficiency syndrome.
Therefore, dredge mechanism of qi in early days, his disease takes place for the development that prevents the state of an illness, significant.Radix Bupleuri bitter in the mouth suffering in the pharmaceutical composition provided by the invention, be slightly cold, go into liver, gallbladder, pericardium tri-jiao channel, the effect of dispersing the stagnated live-QI to relieve the stagnation of QI, elevate a turnable ladder yang-energy is arranged, Radix Bupleuri can also improve brain blood circulation, strengthens cranial nerve nutrition; The stagnation of liver-QI spleen is considered reciprocal causation, and the Radix Astragali in the present composition, Poria, Semen Ziziphi Spinosae add Pericarpium Citri Reticulatae Viride, Cortex Albiziae, Rhizoma Acori Graminei, Radix Curcumae, Fructus Amomi invigorating spleen and nourishing heart, sedative action.In general, compositions energy soothing liver and strengthening spleen provided by the invention, resolving stagnation for tranquilization.
As used herein, term " necessary component " refers to necessary Chinese medicine medical material, promptly contains the Chinese medicine and the Chinese medicine that contains water-soluble components of volatile oil.
As used herein, term " extract of necessary component " refer to necessary Chinese medicine medical material through the Chinese medicine extraction of routine, concentrate, method such as separation and the material that obtains.
As used herein, term " contain " or " comprising " comprised " comprising ", " basically by ... constitute " and " by ... constitute ".
As used herein, term " basically by ... constitute " refer in compositions, be necessary the component except containing, also can contain a spot of and not influence the submember and/or the impurity of effective ingredient.For example, can contain sweeting agent to improve taste, antioxidant in case oxidation, and other this areas additive commonly used.The Chinese medicine that contains the Chinese medicine of volatile oil and contain water-soluble components accounts at least 30% of pharmaceutical composition gross weight, and preferably at least 60%, more preferably at least 70%.
As used herein, term " aqueous extract " refers to that the Chinese medicine medical material is through water or contain the active component of the extraction with aqueous solution of organic solvent.The content of organic solvent is 0-99.9% (v/v) in the described aqueous solution that contains organic solvent.
As used herein, term " pharmaceutically acceptable carrier " refers to be used for the treatment of the carrier of agent administration, comprises various excipient and diluent.This term refers to some medicament carriers like this: they itself are not necessary active component, and do not have undue toxicity after using.Suitable carriers is well known to those of ordinary skill in the art.(Mack Pub.Co. can find discussing fully about pharmaceutically acceptable excipient in N.J.1991) at Remington ' s Pharmaceutical Sciences.Acceptable carrier can contain liquid on combination of Chinese medicine is learned, as water, saline, glycerol and ethanol.In addition, also may there be complementary material in these carriers, as wetting agent or emulsifying agent, pH buffer substance etc.Other inessential compositions (for example other complementary medical materials) are also included within the definition of pharmaceutically acceptable carrier.
Pharmaceutical composition
In pharmaceutical composition of the present invention, contain or be made of following Chinese medicine medical material as necessary component basically: (a) the 30-200 weight portion contains the Chinese medicine of volatile oil, and the described Chinese medicine that contains volatile oil comprises Rhizoma Cyperi, Rhizoma Acori Graminei, Radix Curcumae and Fructus Amomi; (b) the 100-400 weight portion contains the Chinese medicine of water-soluble components, and the described Chinese medicine that contains water-soluble components comprises Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Cortex Albiziae, Poria, the Radix Astragali, Semen Ziziphi Spinosae and the Radix Paeoniae Alba; And weight (a)+(b) accounts for the 30-99.9% of composition total weight, preferably accounts for the 60-99% of composition total weight, more preferably accounts for the 80-99% of composition total weight.
The Chinese medicine that contains volatile oil of the present invention is selected from Rhizoma Cyperi (Cyperus rotundns), Rhizoma Acori Graminei (Acorus tatarinowii Schott), Radix Curcumae (Curcuma wenyujin Y.H.chen et C.Ling., Curcuma longa L.Liang or Curcuma phaeocaulis Val.) and Fructus Amomi (Amomumvillosum Lour., Amomum villosum Lour.Var.xan thioides T.L.Wuet Senjen or Amomum longiligutarge T.L.Wu).
The Chinese medicine that contains water-soluble components of the present invention is selected from Radix Bupleuri (Bupleurum chinense DC. or Bupleurum scorzonerifolium willd.), Pericarpium Citri Reticulatae Viride (Citms reticulata Blanco), Cortex Albiziae (Albizia julibrissin Durazz.), Poria (Poria cocos (schw) Wolf), the Radix Astragali (Astragalus membranaceus (Fisch.) Bge var.mongholicus (Bge) Hsiao or Astragalus membranaceus (Fisch.) Bge.), the Semen Ziziphi Spinosae (Ziziphus jujuba Mill.var.spinosa (Bunge) Hu ex H.F.chou) and the Radix Paeoniae Alba (Paeonia lactiflcra pall.).
Radix Bupleuri mainly contains saikoside, and next contains plant sterol.Pericarpium Citri Reticulatae Viride mainly contains flavone compound, as Hesperidin, neohesperidin etc., Cortex Albiziae mainly contains saponin, tannin etc., and Poria mainly contains polysaccharide, triterpenes fatty acid composition, the Radix Astragali mainly contains compositions such as saponins, polysaccharide, flavonoid, and Semen Ziziphi Spinosae mainly contains triterpene saponin, as jujuboside A, B, B1, the Radix Paeoniae Alba mainly contains peoniflorin, oxypaeoniflorin, benzoylpaeoniflorin, hydroxyl stem peoniflorin etc.
In another pharmaceutical composition of the present invention, the Chinese medicine medical material also can comprise Fructus Aurantii (Citrus aurantiumL.).Fructus Aurantii mainly contains flavone compound, as Hesperidin, neohesperidin etc.
Except the proportioning by necessary component (medical material) limits the compositions of the present invention, also available Chinese medicine extract limits compositions of the present invention.
In the present composition, contain the aqueous extract of following Chinese medicine medical material: Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Fructus Aurantii, Cortex Albiziae, Poria, the Radix Astragali, Semen Ziziphi Spinosae or the Radix Paeoniae Alba; The volatile oil and the water extract that contain following Chinese medicine medical material: Rhizoma Cyperi, Rhizoma Acori Graminei, Radix Curcumae or Fructus Amomi.The material of surplus is pharmaceutically acceptable carrier, for example starch, maltodextrin etc.
Described aqueous extract preferably contains the active component of the extraction with aqueous solution of ethanol 40-95% (v/v); It more preferably is the active component that contains the extraction with aqueous solution of ethanol 60-85% (v/v).
The inventor has set up a cover and has detected in the said preparation high performance liquid chromatogram (HPLC) of active component in the Chinese crude drug or thin layer chromatography (TLC) assay method and monitor active component in the preparation, makes preparation that good therapeutic effect be arranged.Wherein content of paeoniflorin is 0.1-1.0%, and Determination of Hesperidin Content is 0.1-1.0%, and the content of astragaloside is 0.01-1, and the content of α-cyperone is 0.01-2.
In the present composition, by weight, the appropriate proportioning of four kinds of necessary medical materials is:
(a) the 30-200 weight portion contains the Chinese medicine of volatile oil, and the described Chinese medicine that contains volatile oil comprises Rhizoma Cyperi, Rhizoma Acori Graminei, Radix Curcumae and Fructus Amomi;
(b) the 100-400 weight portion contains the Chinese medicine of water-soluble components, and the described Chinese medicine that contains water-soluble components comprises Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Cortex Albiziae, Poria, the Radix Astragali, Semen Ziziphi Spinosae and the Radix Paeoniae Alba;
And weight (a)+(b) accounts for the 30-99.9% of composition total weight, preferably 60-99%, more preferably 80-99%.The material of surplus is pharmaceutically acceptable carrier, for example starch, maltodextrin etc.
Pharmaceutical composition of the present invention can be made the dosage form of any routine by conventional method, preferably decoction, granule, tablet, capsule preparations, oral liquid etc.
The preparation of drug combination method
The inventor finds that in the pharmaceutical composition provided by the invention, Rhizoma Cyperi, Rhizoma Acori Graminei, Radix Curcumae, Fructus Amomi mainly contain volatile effective component, therefore, to the volatile oil in this four Chinese medicine thing, adopts steam distillation to extract.
Radix Bupleuri mainly contains saikoside, and next contains plant sterol.Fructus Aurantii, Pericarpium Citri Reticulatae Viride mainly contain flavone compound, as Hesperidin, neohesperidin etc., Cortex Albiziae mainly contains saponin, tannin etc., and Poria mainly contains polysaccharide, triterpenes fatty acid composition, Radix Astragali class mainly contains compositions such as saponins, polysaccharide, flavonoid, and Semen Ziziphi Spinosae mainly contains triterpene saponin, as jujuboside A, B, B1, the Radix Paeoniae Alba mainly contains peoniflorin, oxypaeoniflorin, benzoylpaeoniflorin, hydroxyl stem peoniflorin etc.Their contained main components all water-soluble or ethanol, particularly aquiferous ethanol, the active constituent content height, impurity is few; Aquiferous ethanol both can extract water solublity glycoside composition in addition, can extract pure dissolubility aglycon constituents simultaneously again.The concentration of alcohol of described aquiferous ethanol is 40-95% (v/v), preferably is 50-90%, more preferably is 60-85%.
Pharmaceutical composition of the present invention can be prepared by conventional method, in one embodiment, comprises step:
(1) necessary component is mixed, obtain mixture, described necessary component is the Chinese medicine that (a) 30-200 weight portion contains volatile oil, and the described Chinese medicine that contains volatile oil comprises Rhizoma Cyperi, Rhizoma Acori Graminei, Radix Curcumae and Fructus Amomi; (b) the 100-400 weight portion contains the Chinese medicine of water-soluble components, and the described Chinese medicine that contains water-soluble components comprises Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Cortex Albiziae, Poria, the Radix Astragali, Semen Ziziphi Spinosae and the Radix Paeoniae Alba;
(2) the pharmaceutically acceptable carrier of adding surplus in the mixture of step (1) gained makes the described pharmaceutical composition of claim 1;
And weight (a)+(b) accounts for the 30-99.9% of composition total weight.
In another preference, the method for preparing pharmaceutical composition of the present invention comprises step:
(1) get 30-200 weight portion Rhizoma Cyperi, Rhizoma Acori Graminei, Radix Curcumae, Fructus Amomi and pulverize, add 5-15 times of water, extract volatile oil with steam distillation, carry oily 3-15 hour after, divide and get volatile oil, decoction liquor and medicinal residues;
(2) medicinal residues decoct with water, filter, and the decoction liquor of medicinal liquid and step (1) gained merges concentrated that extractum is standby;
(3) 100-400 weight portion Radix Bupleuri, Fructus Aurantii, Pericarpium Citri Reticulatae Viride, Cortex Albiziae, Poria, the Radix Astragali, Semen Ziziphi Spinosae and the Radix Paeoniae Alba are pulverized, use 40-95% (v/v) ethanol water reflux, extract, 1-5 time, extracting solution filters, and the extractum with step (2) gained behind the recovery ethanol merges;
(4) extract dry, the pulverizing after the merging adds pharmaceutically acceptable carrier, and the volatile oil that sprays into step (1) gained makes pharmaceutical composition provided by the invention.
Purposes
Pharmaceutical composition provided by the invention can be used for treating depression.The dosage of main component is the treatment effective dose, for example every day about 1 mg/kg body weight-Yue 60 mg/kg body weight, preferably this dosage is about 10 mg/kg body weight-Yue 40 mg/kg body weight.Certainly, concrete dosage also should be considered factors such as route of administration, patient health situation, and these all are within the skilled practitioners skill.In addition, pharmaceutical composition of the present invention also can use with the other treatment agent.
Major advantage of the present invention is:
1. the pharmaceutical composition that provides is to liver, the heart, the effect of many target spots of spleen, and excess syndrome, deficiency syndrome are double controls, and effect is obvious;
2. abundant to extraction of active ingredients;
3. with low cost.
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example is usually according to the normal condition or the condition of advising according to manufacturer.Unless otherwise indicated, otherwise all percentage ratio and umber by weight.
Embodiment 1-3
Pharmaceutical compositions
(1) get Rhizoma Cyperi, Rhizoma Acori Graminei, Radix Curcumae, Fructus Amomi pulverizing, add the water of 10 times of amounts, extracted volatile oil about 6 hours with steam distillation, divide and get volatile oil, decoction liquor is standby;
(2) the medicinal residues decocting that adds 8 times of amounts boiled 2 hours, filtered, and medicinal liquid and the merging of above-mentioned decoction liquor are evaporated to relative density and are the extractum of 1.25-1.35 (60 ℃), and be standby;
(3) all the other Radix Bupleuri, Fructus Aurantii, Pericarpium Citri Reticulatae Viride etc. eight flavor pulverizing medicinal materials add 10 times of amount alcohol reflux 3 hours for the first time with 70% alcohol reflux secondary, add the alcohol reflux 2 hours of 8 times of amounts the second time, merge secondary raffinate, filter, behind the recovery ethanol, merge with above-mentioned extractum;
(4) drying under reduced pressure is pulverized, and adds carboxymethyl starch sodium, and adjuvants such as lactose and polyethylene pyrrole Lip river alkane ketone are granulated, and spray into above-mentioned volatile oil, are pressed into 1000, coating, the pharmaceutical composition of embodiment 1-3.
Paeoniflorin content 〉=0.25wt% in the pharmaceutical composition of embodiment 1.
Paeoniflorin content 〉=0.24wt% in the pharmaceutical composition of embodiment 2.
Paeoniflorin content 〉=0.23wt% in the pharmaceutical composition of embodiment 3.
The assay method of peoniflorin: measure according to high performance liquid chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 D).
Chromatographic condition and system suitability test are filler with octadecyl silicon bonded silica gel; Methanol-water-phosphoric acid (30: 70: 0.1) is a mobile phase; The detection wavelength is 230nm.Number of theoretical plate calculates by the peoniflorin peak should be not less than 1500.
It is an amount of that the preparation precision of reference substance solution takes by weighing the peoniflorin reference substance, adds dissolve with methanol, makes the solution that every 1ml contains 50 μ g, in contrast product solution.
10 of this product are got in the preparation of need testing solution, remove coating, porphyrize, and it is fixed to get the accurate title of about 0.5g, put in the 100ml ground tool plug triangular flask, precision adds methanol 25ml, close plug, claim to decide weight, supersound process 30 minutes is put and is chilled to room temperature, claim again to decide weight, add methanol and supply the weight that subtracts mistake, shake up, filter, the accurate subsequent filtrate 5ml that draws puts in the 10ml measuring bottle, add methanol and be diluted to scale, shake up, promptly.
Accurate respectively reference substance solution and each the 10 μ l of need testing solution of drawing of algoscopy inject chromatograph of liquid, measure, promptly.
Embodiment 4
The pharmaceutical composition pharmacodynamics test
Materials and methods
(1) medicine and reagent
The pharmaceutical composition coated tablet that embodiment 2 makes;
Dopamine hydrochloride (DA), 5-hydroxy tryptamine hydrochlorate (5-HT) are available from Sigma company;
5-hydroxyindoleacetic acid (5-HIAA), 3.4-dihydroxyphenyl acetic acid (DOPAC) are available from Switzerland, and other reagent all is analytical pure.
(2) animal SD strain rat, body weight 180-230g, the quality certification number is learned 08-005 number for Shan doctor animal card, available from Xi'an Jiaotong University Medical College's Experimental Animal Center.
(3) administration with draw materials
18 of rats, ♀ ♂ dual-purpose is divided into 3 groups at random, 6 every group, irritates stomach respectively and gives normal saline, obeys pharmaceutical composition 100mg/kg and 200mg/kg that embodiment 2 makes.Every day gastric infusion once, continuous 6 days, 24h sacrificed by decapitation rat was taken out full brain after the last administration, separate brain, cerebral cortex, striatum on the ice bath, weigh with liquid nitrogen curing, put in the glass homogenizer, make tissue homogenate fast, high speed centrifugation, get supernatant 20 μ l, detect (document 1: Acta Pharmaceutica Sinicas such as Zhang Linkui, 1987 by literature method; 22 (8): 591-596, document 2: Chinese J Pharmacol Toxicols such as Yuan Shulan, 1990; 4 (1) 4-8).
(4) instrument
Day island proper Tianjin LC-10A high performance liquid chromatograph, U.S.'s favour spectrum LC-4B electrochemical detector (TC-5 glassy carbon electrode and Ag/Agcl reference electrode), chromatographic column HIQ Sil C18 (4.6mmI.D * 250mm).
Mobile phase: phosphate buffer (mmol/L) [perfluorooctane sulfonate 0.5, EDTA0.27, the mixed liquor (93: 37) of NaHPO480 and citric acid 58 and methanol, pH4.3] flow velocity 0.9ml/min, Electrochemical Detection running voltage 0.7V, range 0-5nA.
The result
Pharmaceutical composition 100mg/kg that embodiment 2 makes and 200mg/kg are to rat hypothalamus 3,4-hydroxyl phenylacetic acid (DOPAC) and 5-hydroxyindole acetic acid (5-HIAA) content have obvious rising effect, and five hydroxytryptamine (5-HT)/5-HIAA ratio is had remarkable reduction effect;
To cerebral cortex, the pharmaceutical composition that 100mg/kg embodiment 2 makes can obviously reduce dopamine (DA)/DOPAC ratio, and 2000mg/kg can reduce 5-HT/5-HIAA ratio;
To striatum, the pharmaceutical composition that 200mg/kg embodiment 2 makes obviously reduces DA content;
Two dosage group DOPAC content all significantly improve, and DA/DOPAC ratio reduces, and it is generally acknowledged that the ratio (T/M) of mediator and its main metabolites reduces the turnover rate increase of meaning mediator, and neuronal activity increases in other words.
The result shows that the pharmaceutical composition that embodiment 2 makes has activation to 5-HT neuron in the rat brain and DA neuron.
Embodiment 5-6
The pharmaceutical composition pharmacodynamic experiment
The pharmaceutical composition coated tablet that makes with embodiment 1 and 3 replaces the medicine among the embodiment 4 to carry out identical test, the result is identical with embodiment 4, shows that the pharmaceutical composition coated tablet that embodiment 1 and 3 makes has activation to 5-HT neuron in the rat brain and DA neuron.
Embodiment 7
Optimum preparation condition
1. the extraction of volatile oil test
Take by weighing Rhizoma Cyperi 240g, Rhizoma Acori Graminei 288g, Radix Curcumae 240g, Fructus Amomi 144g put in the round-bottomed flask, add 10 times of water gagings, soak after 2 hours, connect volatile oil extractor, heating extraction volatile oil, its each period is put forward oil mass and sees Table 1.
Table 1 extraction time is to proposing the influence of oil mass
Table 2 amount of water is to proposing the influence of oil mass
In the table 1,2 as can be seen, the water extraction that adds 10 times of amounts after about 6 hours volatile oil carried to the greatest extent, therefore carry the oil time to can be controlled in about 6 hours, amount of water is 10 times of amounts.
Other gets each three parts of above-mentioned volatile oil medical materials, and parallel assay records its volatile oil and sees Table 3.
Three repeated trials results of table 3
| Numbering | Medical material amount (g) | Amount of water (doubly) | Extraction time (h) | Put forward oil mass (ml) | On average (ml) |
| 1 2 3 | 912 912 912 | 10 10 10 | 6 6 6 | 6.7 6.6 6.7 | 6.7 |
As seen from Table 3, medical material adds the water of 10 times of amounts, extracts and can substantially oil be carried in 6 hours to the greatest extent, tests average oil pump capacity for three groups and is about 6.7ml, accounts for 0.73% of medical material total amount.
2. all the other eight flavor medicinal material extract method screenings
2.1 water extracting method test
Take by weighing Radix Bupleuri 288g, Fructus Aurantii 288g, Pericarpium Citri Reticulatae Viride 288g, Cortex Albiziae 360g, Poria 480g, Radix Astragali 480g, Semen Ziziphi Spinosae 720g, Radix Paeoniae Alba 240g is ground into coarse powder.Add 8 times of water gagings, decoct secondary, each 2 hours, filter, when filtrate decompression was concentrated into relative density and is 1.20-1.25 (60 ℃), drying under reduced pressure was pulverized, extract powder, weigh, with the extract powder yield, Hesperidin and content of paeoniflorin are as investigating index.
2.2 alcohol extraction test
Take by weighing Radix Bupleuri 288g, Fructus Aurantii 288g, Pericarpium Citri Reticulatae Viride 288g, Cortex Albiziae 360g, Poria 480g, Radix Astragali 480g, Semen Ziziphi Spinosae 720g, Radix Paeoniae Alba 240g is ground into coarse powder.Add 8 times of amount 70% ethanol, the backflow secondary each 2 hours, filters merging filtrate, reclaim ethanol, when being evaporated to relative density and being 1.20-1.25 (60 ℃), drying under reduced pressure is pulverized, get extract powder, weigh, with the extract powder yield, Hesperidin and content of paeoniflorin are as investigating index.
2.3 index components assay
(1) Determination of Hesperidin Content is measured
(1) chromatographic condition:
Chromatographic column: Phenomenex ODS C
18Post (4.6 * 150mm, 5 μ m)
Mobile phase: acetonitrile-water-phosphoric acid (20: 80: 0.2);
Detect wavelength: 283nm, detection sensitivity: 0.01AUFS;
Flow velocity: 1ml/min, sample size: 10 μ l.
(2) preparation of contrast solution: it is an amount of that precision takes by weighing the Hesperidin reference substance, adds dehydrated alcohol and make the solution that every 1ml contains 80g, in contrast product solution.
(3) preparation of need testing solution: precision take by weighing water extraction test down extract powder and each 0.7g of extract powder under the alcohol extraction test item, put respectively in the 100ml ground tool plug triangular flask, precision adds methanol 25ml, claims to decide weight, supersound process 30 minutes, put and be chilled to room temperature, claim again to decide weight, add methanol and supply the weight that subtracts mistake, shake up, filter, as need testing solution.
(4) linear relationship: accurate reference substance solution 2.5,5.0,10.0,15.0, the 20.0 μ l sample introductions of drawing, record peak area, carry out regression analysis, get regression equation: A=1262996.25 * C+250.41, r=1.000.
The result shows that Hesperidin is in the 0.216g-1.728g scope, and peak area and concentration are good linear relationship.
(5) recovery test: precision takes by weighing the sample 0.2g of known content, a certain amount of Hesperidin reference substance of accurate adding, and mixing, by the method operation under (3) item, above-mentioned chromatographic condition is measured, and average recovery rate is 97.27% as a result, and RSD is 0.29% (n=6).
(6) determination: accurate respectively contrast solution and each 10 μ l of need testing solution of drawing, inject chromatograph of liquid, measure, promptly.
(2) content of paeoniflorin is measured
(1) chromatographic condition:
Chromatographic column: Phenomenex ODS C
18Post (4.6 * 150mm, 5 μ m);
Mobile phase: methanol-water-phosphoric acid (30: 70: 0.1);
Detect wavelength: 230nm, detection sensitivity 0.01AUFS;
Sample size: 10 μ l.
(2) preparation of reference substance solution: it is an amount of that precision takes by weighing the peoniflorin reference substance, adds dissolve with methanol, makes the solution that every 1ml contains 60 μ g, in contrast product solution.
(3) preparation of need testing solution: precision take by weighing water extraction test down extract powder and each 0.6g of extract powder under the alcohol extraction test item, put respectively in the 100ml ground tool plug triangular flask, precision adds methanol 25ml, claim to decide weight, supersound process 30 minutes is put and is chilled to room temperature, claim again to decide weight, add methanol and supply the weight that subtracts mistake, shake up, filter, the accurate subsequent filtrate 5ml that draws puts in the 10ml measuring bottle, adds methanol and is diluted to scale, shake up, promptly.
(4) linear relationship: accurate reference substance solution 2,4,6,8,10, the 12 μ l sample introductions of drawing, record peak area, carry out regression analysis, get regression equation: A=1322846.75 * C-2201.86, r=1.000, the result shows that peoniflorin is in 0.108 μ g-0.648 μ g scope, and peak area and concentration are good linear relationship.
(5) recovery test: precision takes by weighing the sample 0.2g of known content, accurate a certain amount of peoniflorin reference substance, the mixing of adding, press the operation of need testing solution preparation method, above-mentioned chromatographic condition is measured, and average recovery rate is 98.98% as a result, and RSD is 1.34% (n=6).
(6) determination: accurate respectively contrast solution and each 10 μ l of need testing solution of drawing, inject chromatograph of liquid, measure, promptly.
Press the said determination method, measuring with water and 70% ethanol is that solvent extracts peoniflorin and content of hesperidin in the gained extract powder, the results are shown in Table 4.
The experimental result of two kinds of extracting method of table 4
| Extracting method | Extract powder yield (%) | Content of hesperidin (%) | Paeoniflorin content (%) |
| Water extraction | 4.19 | 0.11 | 0.28 |
| Alcohol extraction | 7.36 | 0.27 | 0.35 |
The result shows, the percentage composition that water extraction method gets the percentage composition of Hesperidin in the extract powder and peoniflorin far below alcohol extraction follow the example of the percentage composition of Hesperidin and the percentage composition of peoniflorin in the extract powder, therefore, choose the extracting method of pure method as this prescription.
2.4 the optimization of extraction process condition is followed the example of in alcohol extraction
Orthogonal test is selected orthogonal experiment method for use for optimizing the process conditions that alcohol extraction is followed the example of, and investigates Different concentrations of alcohol, the solvent multiple, and extraction time, 4 factors of extraction time, the experimental program of 3 levels of each factor sees Table 5.
Table 5 factor level table
| Factor level | A concentration of alcohol (%) | The B extraction time | C extraction time (h) | D ethanol consumption (doubly) |
| 1 2 3 | 50 70 90 | 1 2 3 | 1(0.5、0.5) 2(1、0.5) 3(2、1) | 8(6、6) 10(8、8) 12(10、10) |
Annotate: the numerical value in extraction time and the alcohol adding amount bracket is respectively second and third time extraction time and alcohol adding amount.
Peoniflorin and Determination of Hesperidin Content serve as to investigate index in extract powder yield of extracting with each experiment and the extract powder, select L for use
9(3
4) orthogonal design table experimentizes, and the results are shown in Table 6, and experimental result is carried out variance analysis, the results are shown in Table 7.
Table 6 orthogonal test table and result [L
9(3
4)]
As can be known from Table 6, serve as to investigate index with dried plaster powder yield, secondly A factor extreme difference maximum is the B factor, C factor and D factor are analyzed A from the K value
1＞A
2＞A
3, B
2＞B
3＞B
1, C
3＞C
1＞C
2, D
2＞D
3＞D
1With the peoniflorin percentage composition serves as to investigate index, and secondly A factor extreme difference maximum is B factor, C factor and D factor, analyzes A from the K value
2＞A
3＞A
1, B
2＞B
3＞B
1, C
3＞C
2＞C
1, D
2＞D
1=D
3With the Hesperidin percentage composition serves as to investigate index, and secondly A factor extreme difference maximum is B, C factor and D factor, analyzes A from the K value
2＞A
3＞A
1, B
2＞B
3＞B
1, C
3＞C
2＞=C
1, D
2＞D
3＞D
1
Table 7 The results of analysis of variance
| Soruces of variation | Sum of square of deviations | Degree of freedom | Variance | F | P (significance) | |
| Extract powder yield (%) | A B C D | 9.4101 0.0464 0.1871 0.0643 | 2 2 2 2 | 4.7050 0.0232 0.0936 0.0822 | 57.24 0.28 1.14 1 | ＞0.05 ＜0.10 ＜0.10 ＜0.10 |
| Paeoniflorin content (%) | A B C D | 0.0414 0.0020 0.0011 0.0014 | 2 2 2 2 | 0.0207 0.0010 0.0006 0.0007 | 29.57 1.43 0.86 1 | ＞0.05 ＜0.10 ＜0.10 ＜0.10 |
| Hesperidin contains | A B C D | 0.0203 0.0029 0.0002 0.0005 | 2 2 2 2 | 0.0102 0.0014 0.0001 0.0002 | 51.00 7.00 0.50 1 | ＞0.05 ＜0.10 ＜0.10 ＜0.10 |
| Amount (%) |
F0.10(2.2)＝9.00 F0.05(2.2)＝19.00
From The results of analysis of variance as can be seen, the A factor has significant difference, and the factor affecting difference of B, C, D is not remarkable, and associative list 6 serves as to investigate index with the dried cream powder yield as can be known, and optimised process should be A
1B
2C
3D
2, but the relative amount A of effective ingredient
2Compare A
1High (being effective ingredient and the ratio of dried cream amount) is so in conjunction with curative effect and dose, the A factor is selected A
2, serve as to investigate index with peoniflorin percentage composition and Hesperidin percentage composition, optimised process is A
2B
2C
3D
2In sum, this preparation optimum selection technology is A
2B
2C
3D
2(with 70% alcohol reflux secondary, add 10 times of amount ethanol for the first time, extracted 3 hours; Add for the second time 8 times of amount ethanol, extracted 2 hours, merge extractive liquid, reclaims ethanol).
2.5 optimised process demonstration test
By extraction process optimization experiment result, select the preparation technology of this preparation to extract volatile oil for Rhizoma Cyperi, Rhizoma Acori Graminei, Radix Curcumae, Fructus Amomi four Chinese medicine material, Radix Bupleuri, Fructus Aurantii, Pericarpium Citri Reticulatae Viride, Cortex Albiziae, Poria, the Radix Astragali, Semen Ziziphi Spinosae, the Radix Paeoniae Alba eight flavor medical materials are with 70% ethanol extraction secondary, add for the first time 10 times of amount alcohol refluxs 3 hours, add 8 times alcohol reflux 2 hours for the second time.
Carry out the checking of optimised process by above-mentioned preparation technology, the results are shown in Table 8.
The checking of table 8 optimised process is table as a result
The result shows, said extracted technology the best.
Embodiment 8
The acute toxicity test of animal
By mouse stomach administration (pharmaceutical composition that embodiment 2 makes), the moving phenomenon that reposes less that part mice appearance half an hour is little after the administration, recover next day normal, do not see other tangible poisoning symptom, every day, maximum dosage-feeding was 20g/kg/ day (amounting to crude drug is 256g/kg/ day), was equivalent to Coming-of-Age Day 400 times of consumptions.
Embodiment 8-10
The acute toxicity test of animal
By mouse stomach administration (pharmaceutical composition that embodiment 1,3 makes), do not see tangible poisoning symptom yet.
Embodiment 11
The long term toxicity test of animal
With reference to the requirement of " study of tcm new drug guide " relevant " rat long term toxicity test " of Ministry of Public Health bureau of drug administration promulgation, the pharmaceutical composition clinical course of treatment is 1 month according to the present invention, has carried out the test of 3 months rat cycles long term toxicity.Dosage is 5,2.5,1.25g/kg/ day (amounting to crude drug 64,32,16g/kg/ day).Large, medium and small dosage tissue is equivalent to clinical people and intends 100,50,25 times of consumption.Each organizes processing half animal (10) after 3 months in administration (pharmaceutical composition that embodiment 2 makes) respectively, and 1/2 (10) give over to the convalescent period test in addition.
Be shown to rat continuous irrigation stomach 3 months, three dosage groups of this medicine do not have obvious influence to administration phase and the general shape of convalescent period rat portion.The body weight of administration treated animal and matched group no significant difference, the conventional and all no abnormal change of electrocardiogram of animals urine; Learn in the inspection at blood routine, blood biochemical, gonophore and other projects do not have significant change; Main organs coefficient, tissue pathology checking do not find the histo pathological change relevant with administration, do not find toxic reaction.Convalescent period is not seen the retardance reaction.
The result shows, the long malicious safe dose of rat is 5g/kg/ day, amounts to crude drug 64g/kg/ day, is equivalent to clinical people and intends with dosage 100 times.
Embodiment 12-13
The long term toxicity test of animal
By the pharmaceutical composition that the method afford embodiment 1,3 of embodiment 11 makes, obtain similar result and give rat continuous irrigation stomach 3 months, three dosage groups do not have obvious influence to administration phase and the general shape of convalescent period rat portion.The body weight of administration treated animal and matched group no significant difference, the conventional and all no abnormal change of electrocardiogram of animals urine; Learn in the inspection at blood routine, blood biochemical, gonophore and other projects do not have significant change; Main organs coefficient, tissue pathology checking do not find the histo pathological change relevant with administration, do not find toxic reaction.Convalescent period is not seen the retardance reaction.
Embodiment 14
Stability test
(1) test apparatus and medicine
1, test apparatus
High performance liquid chromatograph (U.S. TSP company, detector UV100; Infusion pump P-100; The ANASTAR work station), and chromatographic column (Phenomenex ODS C18 post (4.6 * 150mm, 5um)
UV-1100 UV, visible light spectrophotometric spectra meter (BeiJing, China's Rayleigh is analyzed company)
AE240 double-range electronic analytical balance (Switzerland METTLER TOLEDO)
GNP type water isolation type constant incubator (going up the grand experimental facilities company limited of Nereid)
Three usefulness ultraviolet instrument UV-8 (BEI JING XING CHENG)
Intelligence disintegration tester ZB-IB type (Precision Instrument Factory, Tianjin Univ.)
Chromatography cylinder and do the required corresponding instrument of limit test of microbe
2, medicine
The pharmaceutical composition that embodiment 2 makes
(2) experiment condition
1, accelerated test:
Medicine is put 40 ℃ ± 2 ℃ of temperature, placed 6 months under relative humidity 75% ± 5% condition, respectively at 1st month, the 2nd month, the 3rd month, the 6th sampling at the end of month detected.
2, long term test
Medicine is put 25 ℃ ± 2 ℃ of temperature, place under the condition of relative humidity 60% ± 10%, detect respectively at sampling in 0 month, 3 months, 6 months, 9 months, 12 months.
(3) detection method
Referring to the method for measuring Hesperidin and peoniflorin among the embodiment 7.
(4) testing result
The results are shown in Table 9-10.
Table 9 accelerated test result
Table 10 long-term test results
The result shows
The pharmaceutical composition that embodiment 2 makes is 40 ℃ ± 2 ℃ of temperature, placed 6 months under the condition of relative humidity 75% ± 5%, its character, discriminating, disintegration, microbial limit, assay etc. have no significant change, all up to specification, illustrate that this product has good stability.
The pharmaceutical composition that embodiment 2 makes is 25 ℃ of temperature, carried out long-term investigation 12 months under the condition of relative humidity 60% ± 10%, its character, discriminating, disintegration, microbial limit, assay etc., have no significant change, all up to specification, illustrate that this product is stable in 12 months under the long term test condition.
Embodiment 15-16
Stability test
The pharmaceutical composition that makes with embodiment 1,3 carries out the test as embodiment 14, obtains similar result, has good stability.
Embodiment 17
Pharmaceutical compositions
(1) get Rhizoma Cyperi, Rhizoma Acori Graminei, Radix Curcumae, Fructus Amomi pulverizing, add the water of 10 times of amounts, extracted volatile oil about 6 hours with steam distillation, divide and get volatile oil, decoction liquor is standby;
(2) the medicinal residues decocting that adds 8 times of amounts boiled 2 hours, filtered, and medicinal liquid and the merging of above-mentioned decoction liquor are evaporated to relative density and are the extractum of 1.25-1.35 (60 ℃), and be standby;
(3) all the other Radix Bupleuri, Pericarpium Citri Reticulatae Viride etc. eight flavor pulverizing medicinal materials add 10 times of amount alcohol reflux 3 hours for the first time with 70% alcohol reflux secondary, add the alcohol reflux 2 hours of 8 times of amounts the second time, merge secondary raffinate, filter, behind the recovery ethanol, merge with above-mentioned extractum;
(4) drying under reduced pressure is pulverized, and adds carboxymethyl starch sodium, and adjuvants such as lactose and polyethylene pyrrole Lip river alkane ketone are granulated, and spray into above-mentioned volatile oil, are pressed into 1000, coating, the pharmaceutical composition of embodiment 17.
Embodiment 18
The pharmaceutical composition that embodiment 17 is made carries out pharmacodynamics test by the method for embodiment 4 respectively, and the result shows and has certain effect, but do not have the prepared pharmaceutical composition effect of embodiment 1-3 remarkable.
All quote in this application as a reference at all documents that the present invention mentions, just quoted as a reference separately as each piece document.Should be understood that in addition those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims institute restricted portion equally.
Claims (10)
1. a pharmaceutical composition is characterized in that, it contains necessary component or its extract that is selected from down group:
(a) the 30-200 weight portion contains the Chinese medicine of volatile oil, and the described Chinese medicine that contains volatile oil comprises Rhizoma Cyperi, Rhizoma Acori Graminei, Radix Curcumae and Fructus Amomi;
(b) the 100-400 weight portion contains the Chinese medicine of water-soluble components, and the described Chinese medicine that contains water-soluble components comprises Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Cortex Albiziae, Poria, the Radix Astragali, Semen Ziziphi Spinosae and the Radix Paeoniae Alba;
And weight (a)+(b) accounts for the 30-99.9% of composition total weight, and the pharmaceutically acceptable carrier of surplus.
2. pharmaceutical composition as claimed in claim 1 is characterized in that, the described Chinese medicine that contains water-soluble components also comprises Fructus Aurantii.
3. pharmaceutical composition as claimed in claim 1 is characterized in that, it contains necessary component or its extract that is selected from down group:
10-40 weight portion Radix Bupleuri;
10-40 weight portion Rhizoma Cyperi;
10-40 weight portion Fructus Aurantii;
10-40 weight portion Pericarpium Citri Reticulatae Viride;
10-50 weight portion Cortex Albiziae;
10-40 weight portion Rhizoma Acori Graminei;
10-40 weight portion Radix Curcumae;
20-60 weight portion Poria;
The 20-60 weight portion Radix Astragali;
5-30 weight portion Fructus Amomi;
30-100 weight portion Semen Ziziphi Spinosae;
The 10-40 weight portion Radix Paeoniae Alba.
4. pharmaceutical composition as claimed in claim 3 is characterized in that, following medicinal substances extract is an aqueous extract: Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Fructus Aurantii, Cortex Albiziae, Poria, the Radix Astragali, Semen Ziziphi Spinosae or the Radix Paeoniae Alba;
Following medicinal substances extract is volatile oil and water extract: Rhizoma Cyperi, Rhizoma Acori Graminei, Radix Curcumae or Fructus Amomi.
5. pharmaceutical composition as claimed in claim 1 is characterized in that, in described compositions, content of paeoniflorin is 0.1-1.0wt%.
6. pharmaceutical composition as claimed in claim 1 is characterized in that, the dosage form of described compositions is tablet, decoction, granule, capsule preparations, oral liquid.
7. a dietary supplement is characterized in that, it contains necessary component or its extract that is selected from down group:
(a) the 30-200 weight portion contains the Chinese medicine of volatile oil, and the described Chinese medicine that contains volatile oil comprises Rhizoma Cyperi, Rhizoma Acori Graminei, Radix Curcumae and Fructus Amomi;
(b) the 100-400 weight portion contains the Chinese medicine of water-soluble components, and the described Chinese medicine that contains water-soluble components comprises Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Cortex Albiziae, Poria, the Radix Astragali, Semen Ziziphi Spinosae and the Radix Paeoniae Alba;
And weight (a)+(b) accounts for the 30-99.9% of composition total weight, and the pharmaceutically acceptable carrier of surplus.
8. preparation of drug combination method as claimed in claim 1 is characterized in that it comprises step:
(1) necessary component or its extract are mixed, obtain mixture, described necessary component is the Chinese medicine that (a) 30-200 weight portion contains volatile oil, and the described Chinese medicine that contains volatile oil comprises Rhizoma Cyperi, Rhizoma Acori Graminei, Radix Curcumae and Fructus Amomi; (b) the 100-400 weight portion contains the Chinese medicine of water-soluble components, and the described Chinese medicine that contains water-soluble components comprises Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Cortex Albiziae, Poria, the Radix Astragali, Semen Ziziphi Spinosae and the Radix Paeoniae Alba;
(2) the pharmaceutically acceptable carrier of adding surplus in the mixture of step (1) gained makes the described pharmaceutical composition of claim 1;
And weight (a)+(b) accounts for the 30-99.9% of composition total weight.
9. preparation method as claimed in claim 8 is characterized in that it comprises step:
(1) necessary component or its extract are mixed, obtain mixture, described necessary component comprises 10-40 weight portion Radix Bupleuri, 10-40 weight portion Rhizoma Cyperi, 10-40 weight portion Fructus Aurantii, 10-40 weight portion Pericarpium Citri Reticulatae Viride, 10-50 weight portion Cortex Albiziae, 10-40 weight portion Rhizoma Acori Graminei, 10-40 weight portion Radix Curcumae, 20-60 weight portion Poria, the 20-60 weight portion Radix Astragali, 5-30 weight portion Fructus Amomi, 30-100 weight portion Semen Ziziphi Spinosae, the 10-40 weight portion Radix Paeoniae Alba;
(2) the pharmaceutically acceptable carrier of adding surplus in the mixture of step (1) gained makes the described pharmaceutical composition of claim 1.
10. the purposes of the extract of a mixture or described mixture, described mixture contains the Chinese medicine that (a) 30-200 weight portion contains volatile oil, and the described Chinese medicine that contains volatile oil comprises Rhizoma Cyperi, Rhizoma Acori Graminei, Radix Curcumae and Fructus Amomi; (b) the 100-400 weight portion contains the Chinese medicine of water-soluble components, and the described Chinese medicine that contains water-soluble components comprises Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Cortex Albiziae, Poria, the Radix Astragali, Semen Ziziphi Spinosae and the Radix Paeoniae Alba, it is characterized in that, is used to prepare the medicine for the treatment of depression.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710041130XA CN101310758B (en) | 2007-05-24 | 2007-05-24 | Anti-anxiety compound traditional Chinese medicine and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710041130XA CN101310758B (en) | 2007-05-24 | 2007-05-24 | Anti-anxiety compound traditional Chinese medicine and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101310758A true CN101310758A (en) | 2008-11-26 |
| CN101310758B CN101310758B (en) | 2011-12-21 |
Family
ID=40099715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710041130XA Active CN101310758B (en) | 2007-05-24 | 2007-05-24 | Anti-anxiety compound traditional Chinese medicine and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101310758B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102198253A (en) * | 2011-05-27 | 2011-09-28 | 上海市中医医院 | Traditional Chinese medicine composition for resisting depression, and preparation method as well as application thereof |
| CN102940857A (en) * | 2012-12-17 | 2013-02-27 | 成都中医药大学 | Medicine composition for treating depression and preparation method thereof |
| CN105106875A (en) * | 2015-10-12 | 2015-12-02 | 黄名珠 | Medicine for treating depression |
| CN105213966A (en) * | 2015-09-29 | 2016-01-06 | 邢冬梅 | A kind of chronic heart failure merges depressed Chinese medicine preparation and preparation method thereof |
| CN105641148A (en) * | 2016-02-26 | 2016-06-08 | 辽宁中医药大学 | Application of bitter orange volatile oil extract in preparation of antidepressant drug |
-
2007
- 2007-05-24 CN CN200710041130XA patent/CN101310758B/en active Active
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102198253A (en) * | 2011-05-27 | 2011-09-28 | 上海市中医医院 | Traditional Chinese medicine composition for resisting depression, and preparation method as well as application thereof |
| CN102198253B (en) * | 2011-05-27 | 2012-09-05 | 上海市中医医院 | Traditional Chinese medicine composition for resisting depression, and preparation method as well as application thereof |
| CN102940857A (en) * | 2012-12-17 | 2013-02-27 | 成都中医药大学 | Medicine composition for treating depression and preparation method thereof |
| CN105213966A (en) * | 2015-09-29 | 2016-01-06 | 邢冬梅 | A kind of chronic heart failure merges depressed Chinese medicine preparation and preparation method thereof |
| CN105106875A (en) * | 2015-10-12 | 2015-12-02 | 黄名珠 | Medicine for treating depression |
| CN105641148A (en) * | 2016-02-26 | 2016-06-08 | 辽宁中医药大学 | Application of bitter orange volatile oil extract in preparation of antidepressant drug |
| CN105641148B (en) * | 2016-02-26 | 2019-09-17 | 辽宁中医药大学 | Application of the Fructus Aurantii volatile oil extract as preparation antidepressant |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101310758B (en) | 2011-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Cytotoxicity and antihyperglycemic effect of minor constituents from Rhizoma Coptis in HepG2 cells | |
| Liu et al. | Potential antidepressant properties of Radix polygalae (Yuan Zhi) | |
| US7422760B2 (en) | Plant-based medicament for the treatment of Hepatitis C | |
| US20080233220A1 (en) | Further Medical Use Of A Botanical Drug Or Dietary Supplement | |
| Wang et al. | Ethnopharmacological use, pharmacology, toxicology, phytochemistry, and progress in Chinese crude drug processing of the lateral root of Aconitum carmichaelii Debeaux.(Fuzi): a review | |
| JP6449448B2 (en) | Pharmaceutical composition for the treatment and prevention of neurodegenerative disorders comprising, as an active ingredient, button root bark, Angelica dafrika root, Mishima psycho root or a fraction thereof | |
| CN101732461B (en) | Composition for improving brain function and/or treating encephalopathy | |
| CN101310758B (en) | Anti-anxiety compound traditional Chinese medicine and preparation method thereof | |
| CN102120015A (en) | Traditional Chinese medicine for soothing liver and dispersing depressed vital energy and soothing nerves and sedating mind, and preparation method and quality standard thereof | |
| CN104288245B (en) | Anti-aging and constitutional pharmaceutical composition and preparation method thereof and detection method | |
| EP4190342A1 (en) | Traditional chinese medicine composition having mental relief and antidepressant effects and preparation method therefor | |
| Li | Chinese herbal medicine | |
| CN102145089B (en) | Traditional Chinese medicine for treating heart failure | |
| CN103349671A (en) | Resveratrol and spirulina composition and preparations and preparation method thereof | |
| Ma et al. | A review of the ethnopharmacology, phytochemistry, pharmacology, pharmacokinetics and quality control of Paeonia lactiflora Pall. | |
| CN101317964A (en) | Chinese medicinal composition with spleen-enlivening and kidney-tonifying function, preparation and uses thereof | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN107496725B (en) | Composition containing Malus hupehensis and bamboo extract as effective components and application thereof | |
| CN100594913C (en) | Medicine combination for curing diabetes and complication thereof and the preparing method and purpose | |
| CN106038679B (en) | Medicine with treatment effect on both cervical spondylosis and insomnia and preparation method thereof | |
| CN107648565A (en) | A kind of pharmaceutical composition for treating depression and preparation method thereof | |
| CN103664568B (en) | Dendrobium loddigesii Rolfe dimerization stilbene compound and its preparation method and application | |
| CN101310740B (en) | Anti-anxiety compound traditional Chinese medicine and preparation method thereof | |
| CN102430001B (en) | Compound rose-hip flavone preparation for preventing diabetes mellitus and preparation method thereof | |
| CN105193887A (en) | Acanthopanax senticosus extract and antioxidation application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANGHAI SHUANGJI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHANGHAI XINSHENGYUAN PHARMACEUTICAL CO., LTD. Effective date: 20111026 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201203 PUDONG NEW AREA, SHANGHAI TO: 201319 PUDONG NEW AREA, SHANGHAI |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20111026 Address after: 201319 585 Cambridge East Road, Cambridge Industrial Zone, Shanghai, Pudong New Area Applicant after: Shanghai Shuangji Pharmaceutical Co., Ltd. Address before: 201203, Zhang Heng road 1599, Zhangjiang hi tech park, Shanghai, Pudong New Area Applicant before: Shanghai Lisheng Pharmaceutical Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170717 Address after: 201319 Shanghai Free Trade Zone, Cambridge East Road, No. 583 Patentee after: Shanghai Xin Sheng Pharmaceutical (Group) Co., Ltd. Address before: 201319 585 Cambridge East Road, Cambridge Industrial Zone, Shanghai, Pudong New Area Patentee before: Shanghai Shuangji Pharmaceutical Co., Ltd. |
|
| TR01 | Transfer of patent right |